Skip to main content
GEHC logo

GE HealthCare Technologies Inc. (GEHC) Stock: Price, Forecast & Analyst Target

GE HealthCare Technologies Inc. (GEHC) — MoonshotScore 74/100 (Strong band), calculated Nov 18, 2026. Price $81.89 (-2.12%), as of the Nov 19, 2026 trading session; market cap $37.0B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$81.89 −$1.77 (-2.12%) Market Cap $37.0B

GE HealthCare Technologies Inc. · GEHC · NASDAQ · Healthcare · Medical - Devices

Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): GE HealthCare sells diagnostic imaging systems, ultrasound platforms, bedside care equipment, services, digital tools, and the agents clinicians administer to make scans more informative. Its breadth matters only if improved supply execution and longer-cycle orders produce steadier profit and cash while debt remains far above cash.

Price as of Nov 19, 2026

Key Statistics

74 of 100

MoonshotScore v2 · GE HealthCare Technologies (GEHC)

Strong
Business Quality Elite (80)
Financial Safety Okay (45)
Valuation Fair (66)
Growth Durability Flat (48)
Momentum Surging (88)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $5.51B (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 7 of the last 8 reports
  • expected results Feb 3, 2027

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GEHC (57 recorded, newest six shown)
RecordedScoreBand
73Strong
73Strong
77Strong
77Strong
74Strong
74Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$81.89
Change on the day-2.12%
52-week range$58.75–$89.77
Market capitalisation$37.0B—
Price / earnings (trailing)17.27
Shares traded on the day2.84M
Beta (volatility vs the S&P 500)0.77

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $61, high $87, latest $82. $87 $61 high $87 Oct 17, 2025 Nov 19, 2026 · $82 $74Oct 17, 2025$75Oct 31, 2025$73Nov 14, 2025$80Nov 28, 2025$84Dec 12, 2025$84Dec 26, 2025$87Jan 9, 2026$80Jan 23, 2026$81Feb 6, 2026$84Feb 20, 2026$74Mar 6, 2026$70Mar 20, 2026$70Apr 2, 2026$75Apr 17, 2026$61May 1, 2026$61May 15, 2026$62May 29, 2026$65Jun 12, 2026$66Jun 26, 2026$65Jul 10, 2026$61Jul 24, 2026$72Aug 7, 2026$75Aug 21, 2026$69Sep 4, 2026$64Sep 18, 2026$64Oct 2, 2026$70Oct 16, 2026$77Oct 30, 2026$83Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for GE HealthCare Technologies (GEHC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Moderate
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is GE HealthCare Technologies (GEHC), and what does it report?

Short answer · as of

GE HealthCare is not merely a scanner manufacturer. It supplies imaging and ultrasound equipment, patient monitoring and anesthesia products, diagnostic pharmaceuticals, consumables, services, and digital platforms to hospitals, clinicians, radiology practices, and nuclear medicine providers.

Reported company results therefore combine capital-equipment demand, service and consumable activity, and scan-linked pharmaceutical use. Imaging contributes the largest amount among the disclosed segment revenues, while Patient Care Solutions and Pharmaceutical Diagnostics add materially different demand patterns.

2 · Latest results

What do the latest results show for GE HealthCare Technologies (GEHC)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $5.51B.

Revenue, gross profit, operating profit, and net income all advanced from the preceding reported period and from the comparable period. The latest reported revenue and earnings also cleared estimates, following a report in which revenue exceeded expectations while earnings fell short.

Management expects easing supply constraints to support sales and margins, with execution focused on volume and margin recovery. It also says orders for products with longer conversion cycles should contribute more meaningfully later, making that conversion an outlook claim that still requires confirmation in reported revenue and cash flow.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$5.51B$614M$1.36 (diluted)
Q2 FY2026$5.29B$573M$1.24 (diluted)
Q1 FY2026$5.13B$389M$0.85 (diluted)
Q4 FY2025$5.70B$589M$1.29 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for GE HealthCare Technologies (GEHC)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Revenue has expanded across the annual series, while net income recovered from its recent low but remains below earlier levels. Most reported periods produced positive operating cash flow, yet the latest period swung negative and capital spending deepened the cash outflow.

Cash has fallen markedly across the reported window, and debt remains far above cash. Current assets only narrowly cover current liabilities, while the more liquid asset measure falls short; repeated cash outflows would therefore tighten financial flexibility.

Supply disruption is especially consequential here because it can restrain equipment volume and margins while long sales cycles postpone revenue recognition. That combination can leave improving accounting profit disconnected from cash generation.

4 · What to check next?

What should you watch next at GE HealthCare Technologies (GEHC)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

The next earnings release needs to extend the recent gains in revenue and operating profit while showing that anticipated supply improvement is reaching volume and margins. Positive operating cash flow would strengthen that signal; another divergence between profit and cash would weaken it.

Cash relative to debt deserves continued attention, as does the conversion of longer-cycle orders into revenue. Consensus estimates assume continued revenue and earnings growth across future annual periods, so stalled conversion or continued cash depletion would challenge the expected trajectory.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does GE HealthCare Technologies compare with its peers?

Short answer

GE HealthCare Technologies's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

GE HealthCare participates across the clinical workflow: it sells scanners and ultrasound systems, equips bedside care, and supplies contrast media and molecular imaging agents used during diagnostic procedures. That creates exposure to hospital equipment purchases, service activity, consumable use, and procedure-linked pharmaceutical demand.

Imaging dominates the disclosed segment mix, but Patient Care Solutions and Pharmaceutical Diagnostics distinguish the company from a focused scanner or monitoring peer. The breadth reduces reliance on a narrow product category while tying execution to hospital budgets, procedure activity, manufacturing supply, and complex sales cycles.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BeOne Medicines Ltd. (ONC) Named competitor$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 19, 2026$12.5B84 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$175.34 Nov 19, 2026$49.4B83 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Named competitor$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.47 Nov 19, 2026$19.2B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
GE HealthCare Technologies (GEHC) — this page$81.89$37.0B74

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$67.00 – $95.00
Consensus target
$81.22
Median target
$80.00

Consensus record · Captured .

Measured against a quoted price of $81.89 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026

Transactions
23
Identified insiders
10
Purchases
0
Sales
0
Other transactions
23

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GEHC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GEHC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about GE HealthCare Technologies (GEHC)?

Read these with our analysis →

What Investors Ask About GE HealthCare Technologies (GEHC) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How do GE HealthCare imaging systems and Pharmaceutical Diagnostics fit together?

The company sells imaging equipment as well as contrast media and molecular imaging agents administered for diagnostic procedures. Revenue therefore reflects equipment placement and scan-related pharmaceutical demand rather than scanner sales alone.

Why can GE HealthCare orders take time to appear as revenue?

Management says some products have longer sales conversion cycles, so booked demand may not contribute meaningfully to revenue until later. Reported sales and cash generation must confirm that those orders are converting.

Is Imaging the largest disclosed GE HealthCare segment?

Imaging contributes the most revenue among the segments in the disclosed breakdown. Patient Care Solutions and Pharmaceutical Diagnostics remain meaningful because they connect GE HealthCare to bedside care and procedure-linked agents beyond large imaging equipment.

Why should investors watch GE HealthCare cash conversion?

Profit improved in the latest reported period, but operating cash flow turned negative and cash continued to decline. Sustained positive cash generation would show that better operating results are translating into balance-sheet capacity.

What is the GEHC stock price today?

The last price recorded for GE HealthCare Technologies Inc. (GEHC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GEHC price target?

The analyst consensus price target for GE HealthCare Technologies Inc. (GEHC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Management outlook — dated call excerpts; Cash, investments and debt
  • 1. What is GE HealthCare Technologies (GEHC), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for GE HealthCare Technologies (GEHC)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for GE HealthCare Technologies (GEHC)?: Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash, investments and debt; Cash against market value; Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • 4. What should you watch next at GE HealthCare Technologies (GEHC)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash against market value; Management outlook — dated call excerpts
  • 5. How does GE HealthCare Technologies compare with its peers?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: How do GE HealthCare imaging systems and Pharmaceutical Diagnostics fit together?: Business description; Revenue by segment
  • FAQ: Why can GE HealthCare orders take time to appear as revenue?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions)
  • FAQ: Is Imaging the largest disclosed GE HealthCare segment?: Revenue by segment; Business description
  • FAQ: Why should investors watch GE HealthCare cash conversion?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash, investments and debt
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold GEHC

Funds in our ETF coverage that list GEHC among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
LGHT ETF9.74%